- Home
- UNCY vs CRVO Comparison
UNCY vs CRVO Comparison
Compare UNCY & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- CRVO
- Stock Information
- Founded
- UNCY 2016
- CRVO 2001
- Country
- UNCY United States
- CRVO United States
- Employees
- UNCY N/A
- CRVO N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- CRVO Health Care
- Exchange
- UNCY Nasdaq
- CRVO Nasdaq
- Market Cap
- UNCY 74.2M
- CRVO 67.4M
- IPO Year
- UNCY 2021
- CRVO N/A
- Fundamental
- Price
- UNCY $4.93
- CRVO $7.60
- Analyst Decision
- UNCY Strong Buy
- CRVO Strong Buy
- Analyst Count
- UNCY 5
- CRVO 6
- Target Price
- UNCY $55.20
- CRVO $19.17
- AVG Volume (30 Days)
- UNCY 419.1K
- CRVO 105.3K
- Earning Date
- UNCY 11-12-2025
- CRVO 11-11-2025
- Dividend Yield
- UNCY N/A
- CRVO N/A
- EPS Growth
- UNCY N/A
- CRVO N/A
- EPS
- UNCY N/A
- CRVO N/A
- Revenue
- UNCY N/A
- CRVO $7,776,968.00
- Revenue This Year
- UNCY N/A
- CRVO N/A
- Revenue Next Year
- UNCY $19,912.34
- CRVO N/A
- P/E Ratio
- UNCY N/A
- CRVO N/A
- Revenue Growth
- UNCY N/A
- CRVO N/A
- 52 Week Low
- UNCY $3.71
- CRVO $1.80
- 52 Week High
- UNCY $11.00
- CRVO $16.94
- Technical
- Relative Strength Index (RSI)
- UNCY 66.90
- CRVO 39.35
- Support Level
- UNCY $4.33
- CRVO $7.84
- Resistance Level
- UNCY $4.81
- CRVO $8.38
- Average True Range (ATR)
- UNCY 0.31
- CRVO 0.53
- MACD
- UNCY 0.04
- CRVO -0.03
- Stochastic Oscillator
- UNCY 70.07
- CRVO 6.58
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.